AstraZeneca PLC (LON:AZN) Given Average Rating of “Moderate Buy” by Analysts

AstraZeneca PLC (LON:AZN) has been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is £153.33.

A number of equities research analysts recently commented on the company. Citigroup increased their price target on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and set a £115 target price on shares of AstraZeneca in a research report on Thursday, June 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a £180 target price on shares of AstraZeneca in a research report on Tuesday, June 9th.

AstraZeneca Trading Down 0.3%

LON AZN opened at £140.24 on Friday. The firm has a market capitalization of £217.49 billion, a P/E ratio of 21.12, a PEG ratio of 0.86 and a beta of 0.21. The business has a fifty day simple moving average of £138.04 and a 200 day simple moving average of £141.13. AstraZeneca has a 12 month low of £101.03 and a 12 month high of £157.32. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.